U01CA261604

MHEALTH MESSAGING TO MOTIVATE QUITLINE USE AND QUITTING AMONG PERSONS LIVING WITH HIV IN VIETNAM (M2Q2-HIV) - 7. PROJECT SUMMARY/ABSTRACT

We propose M2Q2-HIV [mHealth Messaging to Motivate Quitline Use and Quitting Among Persons Living with HIV (PLWH) in Vietnam (M2Q2-HIV)], an adaptation of our current computer-tailored smoking cessation intervention in Vietnam. We seek to promote underused government resources for public health (Quitline) and nicotine replacement therapy (NRT) among PLWH in a sustainable manner.

The intersection of smoking and HIV/AIDS poses a serious public health threat in Vietnam. Vietnam is dealing with these two challenges with parallel rather than integrated plans. Vietnam currently has 431 outpatient clinics for HIV testing, with 188 clinics providing antiretroviral (ARV) treatment, covered by public insurance. Vietnam has set up telephone "Quitline" counseling with trained tobacco treatment specialists who also provide NRT. These clinical (HIV) and public health resources (Quitlines) are not connected, reducing both programs' impact.

To connect these resources, we will adapt our current intervention for computer-tailored, text-based smoking cessation in Vietnam to be specific to PLWH smoking behavior. For example, by addressing HIV stigma via developing motivational and tailored messages written by PLWH smokers. To further increase message relevance for PLWH smokers, we will add a computer-tailoring innovation: a machine-learning, collective intelligence system. Companies like Amazon use collective intelligence systems to continuously learn and adapt to user feedback (e.g., pages liked or products purchased), thus increasing message relevance. We developed the first collective intelligence system for smokers. Our pilot data indicates that the ability to continuously learn may be even more beneficial for smokers who are less ready to quit, such as PLWH.

We will test M2Q2-HIV by conducting a randomized control trial with 600 PLWH smokers in two provinces in northern Vietnam (26 clinics; 9,877 HIV patients). In Aim 1, we will conduct formative work to prepare the M2Q2-HIV system for PLWH smokers. In Aim 2, we will randomize and follow smokers for six months. Our effectiveness hypothesis will evaluate carbon monoxide (CO) verified, six-month, seven-day point prevalence cessation. Process hypotheses will evaluate self-efficacy, Quitline and NRT use, and test our hypothesized model that specific measured processes will partially mediate observed intervention effectiveness.

Using qualitative interviews with key stakeholders and PLWH smokers, Aim 3 will support nationwide M2Q2-HIV dissemination, assessing acceptability and contextual factors guided by the Practical, Robust Implementation and Sustainability Model (PRISM).

This project builds upon a long-standing, successful collaboration between institutions in Vietnam (Ministry of Health, Bach Mai Quitline, Institute of Population Health and Development, Hanoi Medical University) and UMMS. Our team has expertise in smoking cessation, HIV intervention including stigma related to concomitant substance use, and implementation of complex interventions. The Vietnam Ministry of Health is committed to incorporating M2Q2-HIV as a permanent part of the national infrastructure if proven effective.

University Of Massachusetts Medical School

TO IDENTIFY CANCER RISKS AND RISK REDUCTION STRATEGIES, TO IDENTIFY FACTORS THAT CAUSE CANCER IN HUMANS, AND TO DISCOVER AND DEVELOP MECHANISMS FOR CANCER PREVENTION AND PREVENTIVE INTERVENTIONS IN HUMANS. RESEARCH PROGRAMS INCLUDE: (1) CHEMICAL, PHYSICAL AND MOLECULAR CARCINOGENESIS, (2) SCREENING, EARLY DETECTION AND RISK ASSESSMENT, INCLUDING BIOMARKER DISCOVERY, DEVELOPMENT AND VALIDATION, (3) EPIDEMIOLOGY, (4) NUTRITION AND BIOACTIVE FOOD COMPONENTS, (5) IMMUNOLOGY AND VACCINES, (6) FIELD STUDIES AND STATISTICS, (7) CANCER CHEMOPREVENTION AND INTERCEPTION, (8) PRE-CLINICAL AND CLINICAL AGENT DEVELOPMENT, (9) ORGAN SITE STUDIES AND CLINICAL TRIALS, (10) HEALTH-RELATED QUALITY OF LIFE AND PATIENT-CENTERED OUTCOMES, AND (11) SUPPORTIVE CARE AND MANAGEMENT OF SYMPTOMS AND TOXICITIES. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO STIMULATE TECHNICAL INNOVATION, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, AND FOSTER PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS.

93.393 - Cancer Cause and Prevention Research

National Cancer Institute (NCI) [HHS - NIH]

Worcester, Massachusetts 01655 United States

Single Zip Code

Tobacco Use and HIV in Low and Middle-Income Countries (U01 Clinical Trial Optional) (RFA-CA-20-037)

Amendment Since initial award the total obligations have increased 363% from $750,448 to $3,472,107.